CRISPR Therapeutics AG (CRSP) is a publicly traded Healthcare sector company. As of May 20, 2026, CRSP trades at $48.67 with a market cap of $4.68B and a P/E ratio of -7.51. CRSP moved +2.03% today. Year to date, CRSP is -11.97%; over the trailing twelve months it is +23.69%. Its 52-week range spans $30.04 to $78.48. Analyst consensus is buy with an average price target of $75.00. Rallies surfaces CRSP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes CRSP SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $48.67 |
| Market Cap | $4.68B |
| P/E Ratio | -7.51 |
| EPS | $-6.47 |
| Dividend Yield | 0.00% |
| 52-Week High | $78.48 |
| 52-Week Low | $30.04 |
| Volume | 1.52M |
| Avg Volume | 0 |
| Revenue (TTM) | $3.51M |
| Net Income | $-581.60M |
| Gross Margin | 0.00% |
14 analysts cover CRSP: 0 strong buy, 10 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $75.00.